GNPX-Genprex, Inc. Trade Idea and Target Price

GNPX Chart

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical stage gene therapy company today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock, par value $0.001 per share at an offering price of $1.05 per share.

This is a good secondary offering right after Food and Drug Administration had granted its experimental cancer treatment a fast-track designation.

Here is a short term trade Idea :

Buy Between $0.90 to $1.30.

Hold for 4-8 months.

Target First $3.50 – Will update next near FDA approval. With Fast track designation this will be interesting play.

Update Feb14th : Stock hit above $5 much early than i expected. Still holding this, will update the target price later.

Update Feb19th: GNPX announced another purchase agreements with institutional investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $3.50 per share . There might be a pull back near this price, which will be a good price to re-enter.

Update Feb 27 2019: GNPX tested the $3.50 area which was a good buying oppourtunity we might see that level again or even below, add up and stay long!!

Stop Loss and Risk:

$0.70. Also there is a risk of reverse stock split so keep an eye on that.

Updated stop loss $1.80.

1 Comment

Leave a Reply

Your email address will not be published.


*